Shay Capital LLC Buys 12,227 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Shay Capital LLC lifted its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 4.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 301,464 shares of the company’s stock after buying an additional 12,227 shares during the quarter. Shay Capital LLC owned approximately 0.56% of Fulcrum Therapeutics worth $1,417,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Millennium Management LLC lifted its holdings in Fulcrum Therapeutics by 224.0% in the 4th quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock worth $358,000 after purchasing an additional 52,628 shares in the last quarter. LMR Partners LLP raised its position in shares of Fulcrum Therapeutics by 367.2% during the 4th quarter. LMR Partners LLP now owns 112,500 shares of the company’s stock valued at $529,000 after buying an additional 154,600 shares in the last quarter. Graham Capital Management L.P. raised its position in Fulcrum Therapeutics by 58.9% during the fourth quarter. Graham Capital Management L.P. now owns 144,942 shares of the company’s stock valued at $681,000 after purchasing an additional 53,726 shares during the period. Bridgeway Capital Management LLC purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $658,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at $94,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Up 17.2%

FULC opened at $6.60 on Friday. The firm has a market cap of $356.26 million, a price-to-earnings ratio of -21.29 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a 12 month low of $2.32 and a 12 month high of $10.13. The stock has a fifty day moving average price of $3.61 and a 200-day moving average price of $3.77.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price for the company in a research report on Thursday. HC Wainwright restated a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.50.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.